Biosimilars approved for treatment of inflammatory rheumatological diseases

Int J Rheum Dis. 2016 Nov;19(11):1043-1048. doi: 10.1111/1756-185X.13037.

Authors

Stephen M Mahler^{1

2}, Andri Wardiana¹, Martina L Jones^{1

2}, Christopher J de Bakker¹, Garry G Graham³, Christopher B Howard^{1

2}

Affiliations

¹ Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.
² Australian Research Council Training Centre for Biopharmaceutical Innovation, University of Queensland, Brisbane, Queensland, Australia.
³ School of Medical Sciences, St Vincent's Hospital, University of New South Wales and Department of Clinical Pharmacology, Sydney, New South Wales, Australia.

PMID: 28032957
DOI: 10.1111/1756-185X.13037

No abstract available

Publication types

Editorial

MeSH terms

Biosimilar Pharmaceuticals*
Humans
Rheumatic Diseases / drug therapy*

Substances

Biosimilar Pharmaceuticals